Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...